Biotech Values

[genisi]

What became of the Neulasta biosilimar BioGeneriX was developing with the now defunct Neose?

The last thing I see is dosing a phase II trial of GlycoPEG-GCSF for the treatment of neutropenia in breast cancer patients vs. 6 mg dose of Neulasta:

http://www.controlled-trials.com/ISRCTN56891934/ISRCTN56891934